Quantitative and QMM--an alternative method to accelerate drug development

Drug development is an essential process in the pharmaceutical industry, but it is also time-consuming and expensive, including pre-clinical, clinical and after-sales markets.

QMM is related to many methods used in modern drug development and product lifecycle management.

Modeling and simulation are increasingly used in drug development because they provide opportunities to synthesize information and make inferences beyond existing research.

MIDD can use large data sets and support the work of agencies like the FDA.

Quantitative systems are proving to be more and more important, and their potential impact is also great.

The empirical model used by QMM has obvious advantages.

In addition, QMM is particularly useful for the development of generic drugs, and this use is often discussed.

Generic drugs usually have a smaller market, which requires more effective development methods to maintain a competitive advantage, while also having a positive impact, because generic drugs are more easily accepted by the public.

In addition, QMM is not only related to drug development.

The advantage of QUARNAM is that it is fast and requires less effort.

On the other hand, the pharmaceutical industry in general is increasingly using digital technology, and this trend shows no signs of stopping.

In the future, QMM may continue to develop and become a more widely used method in the drug development process.

Today, more organizations will be able to adopt QMM, and agencies such as WHO or FDA are currently promoting QMM, so it is becoming more recognized in the development and review of modern generic drugs.

Reference source:

1.

5.
FDA (2017).